Ligands for Target Protein for PROTAC

Target Protein-binding Moiety

The PROTAC molecule consists of a target protein ligand and an E3 ubiquitin ligase ligand, with a linker binds them together. The ligand for target protein will lead to attachment of a PROTAC to the proteins of interest for ubiquitin and subsequent degradation.

Target proteins are usually proteins whose overexpression or accumulation may play important roles in the progress of diseases. Numbers of PROTACs have been developed to degrade kinases (such as MEK, KRAS, CDK and Bcr/Abl), transcription factors (such as p53, STAT, RAR, ER and AR), epigenetic tools (such as HDAC and BET bromodomain) and E3 ligase themselves (such as MDM2).

Ligands for Target Protein for PROTAC Inhibitors & Chemicals

(+)-JQ-1

(JQ1)

Cat. No.: HY-13030

(+)-JQ-1 (JQ1) is a potent, specific, and reversible **BET bromodomain** inhibitor, with IC_{50}s of 77 and 33 nM for the first and second bromodomain (**BRD4(1/2)**). (+)-JQ-1 also activates **autophagy**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

A-1210477-piperazinyl

(PROTAC Mcl1-binding moiety 1)

Cat. No.: HY-125908

A-1210477-piperazinyl is a compound binds to protein myeloid cell leukemia 1 (**MCL1**) used for PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib metabolite M18

(LSN3106729)

Cat. No.: HY-126534

Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a **CDK** inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib metabolite M18 hydrochloride

(LSN3106729 hydrochloride)

Cat. No.: HY-126534A

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a **CDK** inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abemaciclib metabolite M18-d8

(LSN3106729-d8)

Cat. No.: HY-126534S

Abemaciclib metabolite M18-d8 (LSN3106729-d8) is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a **CDK** inhibitor with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ABM-14

Cat. No.: HY-131388

ABM-14 is a ligand for targeting **androgen receptor (AR)** for PROTAC. ABM-14 binds to a ligand for VHL via linker to form ARCC-4 (HY-130492) to degrade AR.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Androgen receptor antagonist 1

Cat. No.: HY-130992

Androgen receptor antagonist 1 is an orally available full **androgen receptor** (**AR**) antagonist with an IC_{50} of 59 nM.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Androstanolone acetate

(Dihydrotestosterone acetate)

Cat. No.: HY-111847

Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to **cIAP1** ligand Bestatin via a linker to form **PROTACs**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

AP1867-2-(carboxymethoxy)

(PROTAC FKBP12-binding moiety 2)

Cat. No.: HY-114420

AP1867-2-(carboxymethoxy), the AP1867 (a synthetic $FKBP12^{F36V}$-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules.



Purity: 96.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AP1867-3-(aminoethoxy)

Cat. No.: HY-129363

AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for **FKBP**. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Apcin-A

Cat. No.: HY-130841

Apcin-A, an Apcin derivative, is an **anaphase-promoting complex (APC)** inhibitor. Apcin-A interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A can be used to synthesize the PROTAC CP5V (HY-130257).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ATRA-hydroxyimino

(CRABP-II ligand 1)

Cat. No.: HY-111839

ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BET-IN-6

Cat. No.: HY-130813

BET-IN-6 is a potent and high affnity **BRD2/BRD4** inhibitor. BET-IN-6 is the **ligand** for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BI-4464

Cat. No.: HY-124625

BI-4464 is a highly selective ATP competitive inhibitor of **PTK2/FAK**, with an **IC_{50}** of 17 nM. A PTK2 ligand for PROTAC.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BMS-1166-N-piperidine-COOH

Cat. No.: HY-131187

BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1. BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC_{50} of 1.4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CBP/p300 ligand 2

Cat. No.: HY-138539

CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCR7 Ligand 1

(CCR7-Cmp2105)

Cat. No.: HY-133073

CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human **CC chemokine receptor 7 (CCR7)** with a K_d of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC_{50} of 7.3 μM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CDK9-IN-10

Cat. No.: HY-130850

CDK9-IN-10 is a potent **CDK9** inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-11

Cat. No.: HY-130852

CDK9-IN-11 is a potent **CDK9** inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ch55-O-C3-NH2

(RAR ligand 1)

Cat. No.: HY-111843

Ch55-O-C3-NH2 (RAR ligand 1) is a Ch 55-based ligand, which targets **RAR**. Ch55-O-C3-NH2 (RAR ligand 1) binds to **cIAP1** ligand Bestatin via a linker to form **SNIPER**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dasatinib carbaldehyde

(BMS-354825 carbaldehyde; PROTAC ABL binding moiety 4) **Cat. No.:** HY-111857

Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desmethyl-QCA276

(PROTAC BRD4-binding moiety 4) **Cat. No.:** HY-44103

Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4), the QCA276-based moiety, binds to cereblon ligand via a linker to form **PROTAC** to degrade **BET**. QCA276 is a BET inhibitor with an IC_{50} of 10 nM, and with a K_i of 2.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desmorpholinyl Navitoclax-NH-Me

(Desmorpholinyl ABT-263-NH-Me) **Cat. No.:** HY-131232

Desmorpholinyl Navitoclax-NH-Me is a **Bcl-xL** inhibitor. Desmorpholinyl Navitoclax-NH-Me and a CRBN ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC BCL-XL degrader XZ739 (HY-133557).



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dimethyl-F-OICR-9429-COOH

Cat. No.: HY-141799

Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DUPA

Cat. No.: HY-111606

DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

EED226-COOH

Cat. No.: HY-130979

EED226-COOH is an EED226-derived ligand for target protein **EED** ligand for PROTAC, binds to a ligand for VHL via linker to form UNC6852 (HY-130708) to degrade PRC2.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Estrone-N-O-C1-amido

(ERα ligand 1) **Cat. No.:** HY-111845

Estrone-N-O-C1-amido (ERα ligand 1) is an Estrone-based estrogen ligand, which targets estrogen receptor α (ERα). Estrone-N-O-C1-amido (ERα ligand 1) binds to **cIAP1** ligand Bestatin via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FN-1501-propionic acid

Cat. No.: HY-130981

FN-1501-propionic acid is a **CDK2/9** ligand for PROTAC. FN-1501-propionic acid and a CRBN ligand have been used to design PROTAC CDK2/9 degrader (HY-130709).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNF5-amido-Me

(PROTAC ABL binding moiety 2) **Cat. No.:** HY-111852

GNF5-amido-Me, the GNF5 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HG-7-85-01-Decyclopropane

(PROTAC ABL binding moiety 3) **Cat. No.:** HY-111855

HG-7-85-01-Decyclopropane, the HG-7-85-01 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

I-BET762 carboxylic acid (Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2)

Cat. No.: HY-107443

I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a **BRD4** inhibitor with a **pIC$_{50}$** of 5.1.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Ibrutinib (PCI-32765)

Cat. No.: HY-10997

Ibrutinib (PCI-32765) is a selective, irreversible **Btk** inhibitor with an **IC$_{50}$** of 0.5 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Imatinib carbaldehyde (CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding moiety 1)

Cat. No.: HY-111849

Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ipatasertib-NH2 (GDC-0068-NH2; RG7440-NH2)

Cat. No.: HY-130988

Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for target protein **AKT** for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ipatasertib-NH2 dihydrochloride (GDC-0068-NH2 dihydrochloride; RG7440-NH2 dihydrochloride)

Cat. No.: HY-130988A

Ipatasertib-NH2 dihydrochloride is a ligand for target protein **AKT** for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAK683-CH2CH2COOH

Cat. No.: HY-130815

MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825)

Cat. No.: HY-107447

N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

N-Deshydroxyethyl Dasatinib-d8

Cat. No.: HY-107447S

N-Deshydroxyethyl Dasatinib-d8 is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

N-piperidine Ibrutinib hydrochloride

Cat. No.: HY-130983

N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent **BTK** inhibitor with **IC$_{50}$**s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively.



Purity: 95.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Navitoclax-piperazine (ABT-263-piperazine)

Cat. No.: HY-44432

Navitoclax-piperazine (ABT-263-piperazine) is a **B-cell lymphoma extra large (BCL-XL)** inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604).



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OICR-9429-N-C2-NH2

Cat. No.: HY-141798

OICR-9429-N-C2-NH2 is a ligand for **Wd40 repeat domain protein 5 (WDR5)** extracted from patent WO2019246570A1, intermediate 2. OICR-9429-N-C2-NH2 can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palbociclib-propargyl

(PROTAC CDK6 ligand 1)

Cat. No.: HY-130296

Palbociclib-propargyl is a ligand for target protein **CDK6** for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC_{50} of 2.1 nM for CDK6.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

PD0325901-O-C2-dioxolane

Cat. No.: HY-131295

PD0325901-O-C2-dioxolane has main portion of **MEK** inhibitor PD0325901.
PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Piperidine-GNE-049-N-Boc

Cat. No.: HY-134592

Piperidine-GNE-049-N-Boc is a **ligand for target protein for PROTAC** of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC Bcl-xL ligand-1

Cat. No.: HY-139304

PROTAC Bcl-xL ligand-1 is a ligand for Bcl-xL that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC BET-binding moiety 1

Cat. No.: HY-107451

PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors.



Purity: 82.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC BET-binding moiety 2

Cat. No.: HY-43723

PROTAC BET-binding moiety 2 is an inhibitor of **BET bromodomain**.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC BRD4 Degrader-7

Cat. No.: HY-136857

PROTAC BRD4 Degrader-7 is a potent **bromodomain BRD4** degrader extracted from patent WO2020055976A1, example 1a, has IC_{50}s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 ligand-1

Cat. No.: HY-129939

PROTAC BRD4 ligand-1 is a potent **BET** inhibitor and a ligand for target BRD4 protein for PROTACT GNE-987 (HY-129937A).



Purity: 99.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PROTAC BRD4 ligand-2

Cat. No.: HY-132942

PROTAC BRD4 ligand-2 is a ligand for target BRD4 protein for **PROTAC** CFT-2718.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4-binding moiety 1

Cat. No.: HY-107442

PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD9-binding moiety 1

Cat. No.: HY-107445

PROTAC BRD9-binding moiety 1 is a compound that binds to **BRD9**, and used for inhibiting **BRD9** activity, based on **PROTAC**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD9-binding moiety 1 hydrochloride

Cat. No.: HY-107445A

PROTAC BRD9-binding moiety 1 hydrochloride is a compound that binds to **BRD9**, and used for inhibiting **BRD9** activity, based on **PROTAC**.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC CDK9 ligand-1

Cat. No.: HY-115729

PROTAC CDK9 ligand-1 is a **CDK9** ligand that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Her3-binding moiety 1

Cat. No.: HY-107444

PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC IRAK4 ligand-1

Cat. No.: HY-129967

PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (**IRAK4**). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966).



Purity: 99.49%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

PROTAC PTK6 ligand-1

Cat. No.: HY-139660

PROTAC PTK6 ligand-1 is an intermediate for BTK kinase inhibitor preparation. PROTAC PTK6 ligand-1 can be used in the synthesis of ARD-61 (HY-139659).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quizartinib

(AC220)

Cat. No.: HY-13001

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II **FLT3 tyrosine kinase** inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC_{50}s of 4.2 and 1.1 nM, respectively.



Purity: 99.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SI-109

Cat. No.: HY-129603

SI-109 is a potent **STAT3 SH2 domain** inhibitor (K_i=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC_{50}=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader **SD-36**.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg

SirReal1-O-propargyl

(PROTAC Sirt2-binding moiety 1)

Cat. No.: HY-107453

SirReal1-O-propargyl is a selective and highly potent **Sirtuin 2 (Sirt2)** inhibitor, with an IC_{50} of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SLF

Cat. No.: HY-114872

SLF is a synthetic ligand for **FK506-binding protein (FKBP)** with an affinity of 3.1 μM for **FKBP51** and an IC_{50} of 2.6 μM for **FKBP12**. SLF can be used in the synthesis of PROTAC.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SLF TFA

Cat. No.: HY-114872A

SLF TFA is a synthetic ligand for **FK506-binding protein (FKBP)** with an affinity of 3.1 μM for **FKBP51** and an IC_{50} of 2.6 μM for **FKBP12**. SLF TFA can be used in the synthesis of PROTAC.



Purity: 95.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SLF-amido-C2-COOH

(PROTAC FKBP12-binding moiety 1)

Cat. No.: HY-107452

SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for **FKBP** (SLF).
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

SMARCA-BD ligand 1 for Protac

Cat. No.: HY-44012

SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMARCA-BD ligand 1 for Protac dihydrochloride

Cat. No.: HY-44012A

SMARCA-BD ligand 1 for Protac dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.



Purity: 95.95%
Clinical Data:
Size: 5 mg, 10 mg, 50 mg, 100 mg

TFC 007

Cat. No.: HY-110167

TFC-007, a selective hematopoietic prostaglandin D synthase (**H-PGDS**) inhibitor, show high inhibitory activity against H-PGDS enzyme (IC_{50} value of 83 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg